Kenes (Kenges) Rakishev Invests in GeneSort
GeneSort is a biotech company that provides oncologists and physicians with innovative high-precision genomic diagnostic tools. The custom validated GeneSort tests use cutting-edge sequencing technologies and advanced analytical tools to produce prognostic, predictive, and therapeutic information about each patient. All this data is then compiled into an individual genetic profile which helps doctors seek the most suitable treatment for their patients. These profiles enable medical professionals to work with smaller amounts of DNA and reduce treatment costs while increasing accuracy and effectiveness.
Kenes (Kenges) Rakishev invested in GeneSort through Singulariteam in 2016 as part of the company’s first fundraising round. In 2017 Singulariteam sold their shares to a Hong Kong investment fund named AID Partners for a significant profit.